Looking for a stock that might be in a good position to beat earnings at its next report? Consider ACADIA Pharmaceuticals Inc.ACAD, a firm in the Medical - Biomedical and Genetics industry, which ...
ACADIA significantly exceeded the Q3 revenue estimates. Nuplazid’s uptake has been solid since launch and the company is improving access and giving away a lot of free samples. Which leads me to ...
ACADIA Pharmaceuticals Inc.ACAD is scheduled to report second-quarter 2017 results on Aug 8 after the closing bell. The company's track record has been dismal. Evidently, ACADIA missed estimates in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results